Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Springfield Clinic, LLP

Neither a doctor nor a teaching hospital

Research payments

$2,011,644

505 payments

Through program year 2025, Springfield Clinic, LLP is reported as receiving $2,011,644 in research payments, across 505 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $639,442 139
2024 Research $311,666 177
2023 Research $350,817 61
2022 Research $84,513 2
2021 Research $88,246 30
2020 Research $253,392 59
2019 Research $283,568 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $872,324 89 payments
  2. E.R. Squibb & Sons, L.L.C. $500,610 14 payments
  3. Gilead Sciences, Inc. $185,849 55 payments
  4. Merck Sharp & Dohme Corporation $143,988 17 payments
  5. F. Hoffmann-La Roche AG $141,784 263 payments
  6. Dr.Reddy's Laboratories,Inc. $83,892 39 payments
  7. Senseonics, Incorporated $43,362 17 payments
  8. Insmed, Inc. $32,336 10 payments
  9. AstraZeneca Pharmaceuticals LP $7,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL $623,633 23 payments
  2. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $155,918 1 payment
  3. Phase III Study of Giredestrant Everolimus VS Everolimus Exemestane in Er Her2 Locally Adv Or MBC $155,868 54 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $152,169 5 payments
  5. Real World Long Term Data Collection for Roche Ophthalmology Products Voyager $141,784 263 payments
  6. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $138,320 5 payments
  7. A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 $116,175 2 payments
  8. A Phase 3 randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan or MabThera $83,892 39 payments
  9. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $47,202 2 payments
  10. Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients $36,447 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record